New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

More and more people are microdosing Ozempic, a popular weight loss drug, due to high costs and uncomfortable side effects.

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

With GLP-1 weight loss comes muscle loss. Gyms and personal trainers are rising to the challenge to help people build it back ...

A new study links semaglutide, the active ingredient in Ozempic and Wegovy, to a higher risk of hair loss, especially in ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.

Workouts at gyms to combat muscle loss caused by GLP-1 drugs are gaining traction, but do they differ from regular strength ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...